Lexeo Therapeutics Files 8-K: Material Agreement, Financials
Ticker: LXEO · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001, $8.00, $7.52, $125 million, $7.9999 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-results, equity-sale
Related Tickers: LXEO
TL;DR
Lexeo Therapeutics (LXEO) filed an 8-K detailing a material definitive agreement, financial results, and equity sales.
AI Summary
Lexeo Therapeutics, Inc. announced on October 16, 2025, the entry into a material definitive agreement. The company also reported on its results of operations and financial condition, and disclosed unregistered sales of equity securities. Additional details regarding other events and financial statements/exhibits were also filed.
Why It Matters
This 8-K filing provides crucial updates on Lexeo Therapeutics' financial health, operational results, and significant contractual agreements, impacting investor understanding of the company's current status.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions and potential dilution, warranting investor attention.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- October 16, 2025 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6, New York, New York 10010 (address) — Principal executive offices
- 001-41855 (identifier) — SEC File Number
- 85-4012572 (identifier) — I.R.S. Employer Identification Number
FAQ
What is the nature of the material definitive agreement entered into by Lexeo Therapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not elaborated upon in the provided text.
What specific results of operations and financial condition are reported?
The filing states that results of operations and financial condition are reported, but the specific financial figures or operational outcomes are not detailed in the provided excerpt.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities, but the quantity, price, or terms of these sales are not specified in the provided text.
What other events are being reported in this 8-K filing?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided excerpt.
When was this 8-K report filed with the SEC?
This 8-K report was filed as of October 17, 2025.
Filing Stats: 3,267 words · 13 min read · ~11 pages · Grade level 15.1 · Accepted 2025-10-17 17:26:14
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
- $8.00 — n Stock "), at a price to the public of $8.00 per share. Under the terms of the Under
- $7.52 — m Shares from the Company at a price of $7.52 per share. In addition, the Company has
- $125 million — fering are expected to be approximately $125 million before deducting underwriting discounts
- $7.9999 — of Common Stock at a purchase price of $7.9999 per Pre-Funded Warrant. The aggregate g
- $10 m — Private Placement will be approximately $10 million, before deducting placement agent
- $122.8 million — 2025, the Company estimates that it had $122.8 million of cash, cash equivalents and investmen
Filing Documents
- d52644d8k.htm (8-K) — 57KB
- d52644dex11.htm (EX-1.1) — 189KB
- d52644dex41.htm (EX-4.1) — 77KB
- d52644dex51.htm (EX-5.1) — 10KB
- d52644dex101.htm (EX-10.1) — 263KB
- d52644dex102.htm (EX-10.2) — 100KB
- d52644dex991.htm (EX-99.1) — 11KB
- g52644g1017131035307.jpg (GRAPHIC) — 4KB
- g52644g1017134120754.jpg (GRAPHIC) — 6KB
- g52644g1017134340401.jpg (GRAPHIC) — 2KB
- 0001193125-25-242652.txt ( ) — 1017KB
- lxeo-20251016.xsd (EX-101.SCH) — 3KB
- lxeo-20251016_lab.xml (EX-101.LAB) — 18KB
- lxeo-20251016_pre.xml (EX-101.PRE) — 11KB
- d52644d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated October 16, 2025, by and between the Company and Leerink Partners LLC 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation 10.1 Form of Securities Purchase Agreement, dated October 16, 2025, by and between the Company and the Purchaser 10.2 Form of Registration Rights Agreement, dated October 16, 2025, by and between the Company and the Purchaser 23.1 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included with the opinion filed as Exhibit 5.1) 99.1 Press Release dated October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2025 Lexeo Therapeutics, Inc. By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer